AACR
June 9, 2025
American Association for Cancer Research (AACR) Annual Meeting, April 25-30, 2025
Year
2025
Target
RVU 305 (PRMT5), ONCO Prime, Novel Targets
Assets in this page
Download assets
- pdf file
Preclinical candidate RVU305, an MTA-cooperative, brain-permeable PRMT5 inhibitor, shows activity in MTAP-deleted tumors resistant to immune checkpoint treatment
Download - pdf file
Discovery of novel synthetic lethal targets for effective and safe colorectal cancer therapies
Download